Guggenheim maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowered the price target to $163 from $165. The adjustment follows the company's fourth-quarter sales report, which ...

The following is a summary of “Circulating Levels of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in Schizophrenia: a systematic review and meta-analysis,” published in the January 2025 issue of ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Cannabis aficionados often emphasize the positive aspects of marijuana and related products, citing a range of generally not ...

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and ...

The proportion of incident cases of schizophrenia associated with cannabis use disorder (CUD) almost tripled from the ...

The Concord Police Department is asking for the public’s help in finding a man who’s been missing since Saturday.

Heavy weed use may be far more dangerous than people realize, according to a pair of studies published in JAMA Network Open.

Thomas White’s MP James Frith has backed The Independent’s campaign for all IPP prisoners to have their sentences reviewed ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

A new study from Canadian researchers has found that the proportion of new schizophrenia cases associated with cannabis use ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.